Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been given a consensus rating of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $26.60.

A number of brokerages recently issued reports on ATXS. JMP Securities assumed coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 11th. Finally, Citizens Jmp upgraded Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st.

Institutional Trading of Astria Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC lifted its holdings in Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares in the last quarter. RA Capital Management L.P. lifted its stake in shares of Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after acquiring an additional 61,457 shares during the period. Vestal Point Capital LP lifted its stake in shares of Astria Therapeutics by 4.5% during the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after acquiring an additional 180,000 shares during the period. Fcpm Iii Services B.V. bought a new position in Astria Therapeutics in the fourth quarter valued at about $25,680,000. Finally, Vanguard Group Inc. increased its position in Astria Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock worth $23,936,000 after purchasing an additional 41,833 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Trading Down 5.9 %

ATXS stock opened at $5.70 on Friday. Astria Therapeutics has a 1-year low of $5.68 and a 1-year high of $14.04. The business’s 50 day moving average is $6.81 and its 200-day moving average is $9.15. The firm has a market cap of $321.67 million, a P/E ratio of -2.73 and a beta of 0.69.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. Sell-side analysts forecast that Astria Therapeutics will post -1.65 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.